4.5 Article

MiR-483-5p controls angiogenesis in vitro and targets serum response factor

Journal

FEBS LETTERS
Volume 585, Issue 19, Pages 3095-3100

Publisher

WILEY
DOI: 10.1016/j.febslet.2011.08.039

Keywords

miRNA; Ischemic; Heart disease; IGF2; Angiogenesis; SRF

Funding

  1. Natural Science Foundation For Younth of Heilongjiang Province [QC2010002]
  2. Natural Science Foundation of China [81070457]
  3. Natural Science Foundation For Younth of China [81101373]
  4. Master Innovation Research Foundation of Hei Longjiang Province [YJSCX2011-326HLJ/YJSCX2011-320HLJ]

Ask authors/readers for more resources

Angiogenesis, a key factor in ischemic heart disease, is rapidly initiated in response to hypoxic or ischemic conditions. MicroRNAs (miRNAs) are endogenously expressed small non-coding RNAs that regulate gene expression at post-transcriptional level. The recent discovery of the involvement of these RNAs in the control of angiogenesis renders them very attractive in the development of new approaches for restoring the angiogenic balance. In the present study, we explored that miR-483-5p, a microRNA embedded in the intron of insulin-like growth factor 2 (Igf2), acts as an endogenous angiogenesis-inhibiting factor. We identified that serum response factor (SRF) is one of miR-483-5p target genes. These findings indicated that the miR-483-5p-SRF pathway may offer a novel strategy for treatment with angiogenesis in ischemic heart disease patients. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available